Kaspersen Small (owllift17)

This study reports the 12-month results of the RADIANCE-HTN (A Study of the ReCor Medical Paradise System in Clinical Hypertension) SOLO trial following unblinding of patients at 6months. The blood pressure (BP)-lowering efficacy and safety of endovascular ultrasound renal denervation (RDN) in the absence (2months) and presence (6months) of antihypertensive medications were previously reported. Patients with daytime ambulatory BP≥135/85mmHg after 4weeks off medication were randomized to RDN (n=74) or sham (n=72) and maintained off medication for 2months. A standardized medication escalation protocol was instituted between 2 and 5months (blinded phase). Rogaratinib molecular weight Between 6 and 12months (unblinded phase), patients received antihypertensive medications at physicians' discretion. Outcomes at 12months included medication burden, change in daytime ambulatory systolic BP (dASBP) and office or home systolic BP (SBP), visit-to-visit variability in SBP, and safety. Sixty-five of 74 RDN patients and 67 of 72 sham patients had 12-month dASBP measurements. The proportion of patients on≥2 medications (27.7% vs. 44.8%; p=0.041), the number of medications (0 vs. 1.4; p=0.015), and defined daily dose (1.4 vs. 2.2; p=0.007) were less with RDN versus sham. The decrease in dASBP from baseline in the RDN group (-16.5 ± 12.9mmHg) remained stable at 12months. The RDN versus sham adjusted difference at 12months was-2.3mmHg (95% confidence interval [CI]-5.9 to 1.3mmHg; p=0.201) for dASBP,-6.3mmHg (95%CI-11.1 to-1.5mmHg; p=0.010) for office SBP, and-3.4mmHg (95%CI-6.9 to 0.1mmHg; p=0.062) for home SBP. Visit-to-visit variability in SBP was smaller in the RDN group. No renal artery injury was detected on computed tomographic or magnetic resonance angiography. Despite unblinding, the BP-lowering effect of RDN was maintained at 12months with fewer prescribed medications compared with sham. Despite unblinding, the BP-lowering effect of RDN was maintained at 12 months with fewer prescribed medications compared with sham. The aim of this study was to explore discharge prescription rates of guideline-directed medical therapy (GDMT), defined as aggregate antiplatelet agent, statin, and ACE inhibitor or angiotensin receptor blocker use after endovascular lower extremity (LE) peripheral vascular intervention. Little is known about contemporary GDMT prescription following LE PVI. Sex, age, and comorbid conditions were related to discharge GDMT prescription among patients undergoing LE PVI for symptomatic peripheral artery disease in the 2014-2018 Vascular Study Group of New England Vascular Quality Initiative. Multivariate logistic regression was used to identify independent predictors of discharge GDMT prescription. Among 12,316 patients, only 47.4% (n=5,844) were discharged on GDMT after LE PVI. Most patients were discharged on antiplatelet agents (95.2%), with statins (83.5%) and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (55.8%) prescribed less often. A higher proportion of patients were osures of greater atherosclerotic disease burden were associated with a greater likelihood of GDMT prescription. However, women and patients with the highest risk for atherothrombosis and limb loss were least likely to be prescribed these agents. Provider- and patient-directed educational efforts are needed to close these treatment gaps.Superior vena cava (SVC) syndrome comprises a constellation of clinical signs and symptoms caused by obstruction of blood flow through the SVC. The management of patients with life-threatening SVC syndrome is evolving from radiation therapy to endovascular therapy as the first-line treatment. There is a paucity of data and societal guidelines with regard to the management of SVC syndrome. This paper aims to update the practicing interventionalists with the contemporary and the evolving therapeutic